Patents by Inventor Jennifer Lynn Gage
Jennifer Lynn Gage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092788Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: ApplicationFiled: September 6, 2023Publication date: March 21, 2024Applicant: Omeros CorporationInventors: Neil S. Cutshall, Jennifer Lynn Gage, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert Von Specht, Loren Michael Price, Jennifer Tsoung, Sudheer Babu Vaddela
-
Patent number: 11807641Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: GrantFiled: December 4, 2020Date of Patent: November 7, 2023Assignee: Omeros CorporationInventors: Michael Cicirelli, Neil S. Cutshall, Jennifer Lynn Gage, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Loren Michael Price, Jennifer Tsoung, Sudheer Babu Vaddela
-
Patent number: 11661418Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: GrantFiled: December 4, 2020Date of Patent: May 30, 2023Assignee: OMEROS CORPORATIONInventors: Neil S. Cutshall, Jennifer Lynn Gage, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Thomas L. Little, Markus Metz, Peter Kurt Nollert Von Specht, Loren Michael Price, Jennifer Tsoung
-
Publication number: 20230145071Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.Type: ApplicationFiled: November 30, 2022Publication date: May 11, 2023Inventors: Neil S. Cutshall, Jennifer Lynn Gage, Franz A. Gruswitz, Juhienah Khalaf, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Jennifer Tsoung, Michael Cicirelli, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Sudheer Babu Vaddela
-
Patent number: 11584714Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.Type: GrantFiled: May 29, 2019Date of Patent: February 21, 2023Assignee: OMEROS CORPORATIONInventors: Neil S. Cutshall, Jennifer Lynn Gage, Franz A. Gruswitz, Juhienah Khalaf, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Jennifer Tsoung, Michael Cicirelli, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Sudheer Babu Vaddela
-
Publication number: 20210179612Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: ApplicationFiled: December 4, 2020Publication date: June 17, 2021Inventors: Neil S. CUTSHALL, Jennifer Lynn GAGE, Do Yeon KWON, Thomas L. LITTLE, Markus METZ, Peter Kurt NOLLERT VON SPECHT, Jennifer TSOUNG, Jeremiah H. NGUYEN, Melinda DAVIS, Robert Huerta LEMUS, Santosh Kumar KESHIPEDDY, Sara Rebecca GOLDSTEIN
-
Publication number: 20210171461Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: ApplicationFiled: December 4, 2020Publication date: June 10, 2021Inventors: Neil S. CUTSHALL, Jennifer Lynn GAGE, Sara Rebecca GOLDSTEIN, Do Yeon KWON, Thomas L. LITTLE, Markus METZ, Peter Kurt NOLLERT VON SPECHT, Jennifer TSOUNG
-
Publication number: 20210171512Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: ApplicationFiled: December 4, 2020Publication date: June 10, 2021Inventors: Neil S. CUTSHALL, Jennifer Lynn GAGE, Sara Rebecca GOLDSTEIN, Santosh Kumar KESHIPEDDY, Do Yeon KWON, Robert Huerta LEMUS, Thomas L. LITTLE, Markus METZ, Peter Kurt NOLLERT VON SPECHT, Loren Michael PRICE, Jennifer TSOUNG
-
Publication number: 20210171531Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.Type: ApplicationFiled: December 4, 2020Publication date: June 10, 2021Inventors: Michael CICIRELLI, Neil S. CUTSHALL, Jennifer Lynn GAGE, Sara Rebecca GOLDSTEIN, Santosh Kumar KESHIPEDDY, Do Yeon KWON, Robert Huerta LEMUS, Thomas L. LITTLE, Markus METZ, Jeremiah H. NGUYEN, Peter Kurt NOLLERT VON SPECHT, Loren Michael PRICE, Jennifer TSOUNG, Sudheer Babu VADDELA
-
Publication number: 20190367452Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.Type: ApplicationFiled: May 29, 2019Publication date: December 5, 2019Inventors: Neil S. Cutshall, Jennifer Lynn Gage, Franz A. Gruswitz, Juhienah Khalaf, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Jennifer Tsoung, Michael Cicirelli, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Sudheer Babu Vaddela
-
Patent number: 10106516Abstract: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.Type: GrantFiled: August 4, 2016Date of Patent: October 23, 2018Assignee: Omeros CorporationInventors: Neil S. Cutshall, Jennifer Lynn Gage, Thomas Neil Wheeler, Thomas L. Little
-
Publication number: 20180118711Abstract: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.Type: ApplicationFiled: September 1, 2017Publication date: May 3, 2018Inventors: Neil S. Cutshall, Jennifer Lynn Gage, Thomas Neil Wheeler
-
Patent number: 9920045Abstract: The invention relates to a novel variable hydrate crystalline form of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the inhibition of PDE10.Type: GrantFiled: November 4, 2016Date of Patent: March 20, 2018Assignee: Omeros CorporationInventors: Ekaterina Albert, Jennifer Leigh Nelson, Christopher Scott Seadeek, Karl Reineke, Marco Jonas, Suba Iyer, Xufeng Sun, Neil S. Cutshall, Jennifer Lynn Gage, Thomas L. Little, Wayne Douglas Luke, Elisabeth C. A. Brot, Michael James McDermott
-
Publication number: 20180057484Abstract: The present invention is directed to an improved process for the preparation of compounds of Formula (II) and Formula (III), which are useful in the inhibition of PDE10. In particular, the present invention is directed to an improved process for the preparation of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, which is useful in the inhibition of PDE10.Type: ApplicationFiled: April 7, 2017Publication date: March 1, 2018Inventors: Neil S. Cutshall, Jennifer Lynn Gage, Thomas L. Little, Wayne Douglas Luke, Elisabeth C. A. Brot, Marco Jonas, Michael James McDermott, Karl E. Reineke
-
Patent number: 9879002Abstract: Isolated or pure compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including but not limited to psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing an isolated or pure compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.Type: GrantFiled: April 22, 2016Date of Patent: January 30, 2018Assignee: Omeros CorporationInventors: Jennifer Lynn Gage, Kevin L. Harbol, Raghuram Bommagani, Durga Varaprasad Botla, Laxma Reddy Karnati, Satyamurthi Narayanan
-
Patent number: 9783521Abstract: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.Type: GrantFiled: January 15, 2013Date of Patent: October 10, 2017Assignee: Omeros CorporationInventors: Neil S. Cutshall, Jennifer Lynn Gage, Thomas Neil Wheeler
-
Publication number: 20170166559Abstract: The invention relates to a novel variable hydrate crystalline form of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the inhibition of PDE10.Type: ApplicationFiled: November 4, 2016Publication date: June 15, 2017Inventors: Ekaterina Albert, Jennifer Leigh Nelson, Christopher Scott Seadeek, Karl Reineke, Marco Jonas, Suba Iyer, Xufeng Sun, Neil S. Cutshall, Jennifer Lynn Gage, Thomas L. Little, Wayne Douglas Luke, Elisabeth C. A. Brot, Michael James McDermott
-
Publication number: 20170152238Abstract: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.Type: ApplicationFiled: August 4, 2016Publication date: June 1, 2017Inventors: Neil S. Cutshall, Jennifer Lynn Gage, Thomas Neil Wheeler, Thomas L. Little
-
Patent number: 9650368Abstract: The present invention is directed to an improved process for the preparation of compounds of Formula (II) and Formula (III), which are useful in the inhibition of PDE10. In particular, the present invention is directed to an improved process for the preparation of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, which is useful in the inhibition of PDE10.Type: GrantFiled: April 24, 2015Date of Patent: May 16, 2017Assignee: Omeros CorporationInventors: Neil S. Cutshall, Jennifer Lynn Gage, Thomas L. Little, Wayne Douglas Luke, Elisabeth C. A. Brot, Marco Jonas, Michael James McDermott, Karl E. Reineke
-
Publication number: 20170022190Abstract: Isolated or pure compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including but not limited to psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing an isolated or pure compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.Type: ApplicationFiled: April 22, 2016Publication date: January 26, 2017Inventors: Jennifer Lynn Gage, Kevin L. Harbol, Raghuram Bommagani, Durga Varaprasad Botla, Laxma Reddy Karnati, Satyamurthi Narayanan